How Long Does the Wegovy Tablet Take to Work?

# How Long Does the Wegovy Tablet Take to Work?

The honest answer: longer than most people expect. And the people who stick with oral Wegovy past the early weeks — when the side effects are most pronounced and the visible results are fewest — are the ones who see the meaningful 15–17% weight loss that the clinical trial data shows is possible.

This guide gives you an evidence-based timeline of what to expect, week by week and month by month, based on the OASIS trial data and the pharmacology of oral semaglutide. It also explains why the drug is designed to be slow, and why that is actually the correct approach.

> Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment. The information in this guide is general and does not replace the advice of your prescribing clinician or the patient information leaflet supplied with your medication.

—

## Why oral Wegovy takes longer than the injection

Before the timeline, it helps to understand why oral semaglutide has a different pace from injectable Wegovy.

The injection delivers semaglutide subcutaneously (under the skin) with around 89% bioavailability — almost all of the injected dose reaches the bloodstream. Oral semaglutide, by contrast, has an oral bioavailability of approximately 1–2% under optimal conditions (with the 30-minute fasting window observed correctly). The SNAC formulation technology makes that small fraction clinically meaningful, but it means you are working with a fundamentally different absorption dynamic.

At the starting dose of 1.5mg, blood semaglutide levels are building. The drug accumulates over weeks — each daily tablet adds to a slowly rising plasma level rather than delivering a single large weekly dose. This means the appetite-suppressive and metabolic effects build gradually rather than arriving quickly.

The implication for expectations: do not judge oral Wegovy by how you feel in week two. Judge it by where you are at month three.

—

## Weeks 1–4: the settling-in phase (1.5mg)

**What is happening pharmacologically:** Semaglutide levels are building in your bloodstream from near zero. You are taking 1.5mg daily — the lowest dose on the escalation schedule — and the drug is establishing its baseline presence.

**What you are likely to feel:** Side effects, primarily. Nausea is the most common experience in week one, and it typically peaks in weeks two and three before beginning to settle. Reduced appetite may be noticeable but is often modest at this stage. You may also notice food tasting slightly different, or feeling full after smaller portions than usual.

**Weight change:** Some people lose 1–3kg in the first four weeks, mostly from reduced calorie intake as appetite reduces and nausea makes eating less appealing. Others see no change on the scale in this period. Neither outcome indicates whether the drug is “working” in any long-term sense — this phase is about tolerating the starting dose, not achieving target weight loss.

**The most common mistake:** Stopping in weeks two to four because “it’s not working.” This is the period of maximum side effects and minimum visible results. It is the hardest part of the treatment journey, and it passes.

—

## Months 2–3: appetite suppression becomes clear (1.5mg transitioning to 4mg)

**What is happening:** Your prescriber will typically move you from 1.5mg to 4mg around week five. Blood semaglutide levels rise further. The appetite-suppressive effects become more consistent and more noticeable.

**What you are likely to feel:** A genuine reduction in hunger between meals. Foods you used to crave may become less compelling. Portion sizes that felt normal before treatment may now feel like too much. The nausea from the starting dose typically settles during this period, though some people experience a brief return when moving to 4mg.

**Weight change:** Most people are seeing 3–5% weight loss by the end of month three. At an average starting weight of 100kg, that is 3–5kg. This is meaningful progress, but it is not the headline number from the clinical trial — that comes later.

—

## Months 3–6: the drug “clicks” (4mg to 9mg)

This is the period that most patients describe as when oral Wegovy “clicked” — when the appetite suppression became a consistent part of daily life rather than an occasional observation.

**What is happening:** At 4mg and moving toward 9mg, semaglutide levels are in the therapeutic range. GLP-1 receptor agonism is having measurable effects on gastric emptying, appetite signalling from the brain, and insulin and glucagon secretion.

**What you are likely to feel:** Consistent reduction in hunger. You may find yourself forgetting to eat, or eating a portion and feeling satisfied quickly and for longer. Many people report that food decisions become easier — the drug reduces the hedonic pull of food, making it less effortful to make lower-calorie choices.

**Weight change:** Average weight loss at six months in the OASIS trial cohort was around 5–8% of body weight. For some people it is more; for others it is at the lower end. The variance at this stage is wider than later in treatment.

—

## Months 6–15: maximum weight loss (9mg to 25mg maintenance)

The OASIS 4 trial ran to 64 weeks (approximately 15 months) and found an average weight loss of **16.6% of body weight** at the full escalation schedule. This is the headline number — and it is achieved over a sustained period, not in the early months.

At 25mg — the maintenance dose reached around week 13 — the drug is at its full therapeutic level. Weight loss at this stage is at its most consistent, though the rate typically slows compared to earlier months as the body approaches a new equilibrium.

**What this means in practice:** For a person starting at 100kg:
– 6 months: approximately 6–8kg lost
– 12 months: approximately 12–14kg lost
– 15 months (full 64-week trial): approximately 16–17kg lost

These are averages. Individual results vary based on adherence to the fasting protocol, diet, physical activity, dose tolerability, and individual metabolic response.

—

## Why you should not stop early

The OASIS trial data includes a critical piece of information: people who stopped oral semaglutide regained a significant proportion of their lost weight. The drug works while you take it. The appetite suppression, the slowed gastric emptying, the reduced food cravings — these are all effects of the medication that diminish when the medication stops.

If you are in weeks two to eight and questioning whether the treatment is working, the clinical evidence suggests that the most important thing you can do is stay the course past this period. The return on continued treatment improves considerably as the dose escalates.

—

## Frequently asked questions

### Why am I not losing weight after two weeks on oral Wegovy?

Two weeks is very early in treatment. At the 1.5mg starting dose, blood semaglutide levels are still building. Most meaningful weight loss begins in months two and three, not weeks one and two. Side effects during the first few weeks are not evidence that the drug is failing — they are evidence that it is present and active in your system.

### Is it working if I feel nauseous?

Nausea is one of the most common and well-documented side effects of semaglutide and is caused by the drug’s effect on GI motility and appetite signalling centres in the brain. Experiencing nausea generally indicates that the drug is pharmacologically active. It is not a pleasant experience, but it typically reduces significantly after the first four to eight weeks.

### How do I know if the Wegovy tablet has stopped working?

If you have been on the maintenance dose (25mg) for more than three months and have seen no weight loss in that period — despite consistent adherence to the fasting protocol and no significant change in diet — discuss this with your prescriber. There is natural variation in response, but persistent non-response may warrant a clinical review.

### What if I miss a dose — does it reset the process?

Missing occasional doses does not restart the process. Semaglutide has a half-life of approximately one week, meaning plasma levels drop gradually rather than immediately. A single missed dose has limited impact. Frequent missed doses, or stopping and restarting repeatedly, will reduce the consistency of the drug’s effects and slow progress.

### Is the injection faster than the tablet?

Yes, in general terms. Injectable Wegovy reaches therapeutic blood levels faster due to its higher bioavailability and weekly dosing at higher absolute doses. Some patients achieve faster initial weight loss with the injection. However, the OASIS trial data for the tablet shows equivalent long-term results in terms of percentage weight loss at maximum dose. The tablet is slower to establish but reaches a comparable endpoint.

—

*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets (oral semaglutide) are a prescription-only medicine available in the UK. Always consult a registered UK healthcare professional before starting any weight management treatment, and follow the patient information leaflet supplied with your medication. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*